Fig. 1 · Structure

Documents & Downloads

GW 7647

Cat. No. A11982 CAS 265129-71-3

PPARα agonist

GW 7647 is a potent and highly selective PPARα agonist (EC50 values are 6, 1100 and 6200 nM for human PPARα, PPARγ and PPARδ receptors respectively).

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
PPARα 6 nM (EC50, Human PPARα)
PPARγ 1.1 μM (EC50, Human PPARγ)
PPARδ 6.2 μM (EC50, Human PPARδ)

Cellular Effect

Cell Line Activity Value Description Reference
COS-7 EC50 0.2 μM Transactivation of human PPARalpha expressed in African green monkey COS7 cells incubated overnight by dual-glo luciferase reporter gene assay [PMID: 26595749]
COS-7 EC50 0.2 μM Transactivation of GAL4-fused human PPARalpha ligand binding domain transfected in african green monkey COS7 cells by luciferase reporter gene assay [PMID: 23130964]
COS-7 EC50 0.23 μM Agonist activity at wild-type human PPARalpha LBD expressed in COS7 cells after 12 hrs by Dual-Glo luciferase assay [PMID: 25022880]
COS-7 EC50 0.23 μM Transactivation of human PPARalpha LBD expressed in african green monkey Cos7 cells co-transfected with fused GAL4-DBD after 14 hrs by Dual-Glo Luciferase reporter gene assay [PMID: 20307981]
COS-7 EC50 0.25 μM Agonist activity at wild-type human PPARalpha Thr279Ala mutant expressed in COS7 cells after 12 hrs by Dual-Glo luciferase assay [PMID: 25022880]
HEK293 EC50 0.021 μM Agonist activity at N-terminal Gal4 fused human PPARalpha LBD transfected in HEK293 cells after 24 hrs by luciferase reporter gene assay [PMID: 27622746]
HEK293 EC50 0.021 μM Agonist activity at GAL4-tagged human PPARalpha ligand binding domain chimeric receptor expressed in HEK293 cells after 24 hrs by luciferase reporter gene assay [PMID: 27591006]
HEK293 EC50 0.026 μM Agonist activity at GAL4N fused human PPARalpha LBD expressed in HEK293 cells co-expressing TK-MH100x4-Luc after 24 hrs by luciferase reporter gene assay [PMID: 28539218]
HEK293 EC50 0.2 μM Transactivation of human GAL4-fused PPARalpha ligand binding domain transfected in HEK293 cells after 18 hrs by dual luciferase reporter gene assay [PMID: 23102891]
HEK293 EC50 0.2 μM Agonist activity at Gal4-fused PPARalpha expressed in HEK293 cells after 18 hrs by dual luciferase reporter gene assay [PMID: 21889235]
HEK293 EC50 0.2 μM Agonist activity at PPARalpha ligand binding domain expressed in HEK293 cells co-expressing GAL4 after 18 hrs by dual-luciferase activity based transactivation assay [PMID: 21742490]
HEK293 EC50 0.2 μM Agonist activity at human PPARalpha expressed in HEK293 cells assessed as receptor transactivation at by luciferase reporter gene assay [PMID: 19791744]
HEK293 IC50 0.46 nM Agonist activity at PPARalpha-LBD expressed in HEK293 cells co-expressing GAL4-DBD after 16 to 19 hrs by beta lactamase reporter gene assay [PMID: 22939697]
HEK293 EC50 0.6 nM Activation of PPARalpha transfected in HEK293 cells after 18 hrs by firefly luciferase reporter gene-based luminescence assay relative to control [PMID: 21800856]
HEK293 EC50 0.89 nM Agonist activity at human PPARalpha expressed in HEK293 cells by luciferase reporter gene assay [PMID: 25305688]
HEK293 EC50 13.6 nM Agonist activity at PPAR-alpha (unknown origin) expressed in HEK293 cells by luciferase reporter gene assay [PMID: 24856059]
HEK293 EC50 7.1 nM Agonist activity at PPAR-alpha (unknown origin) expressed in HEK293 cells by TR-FRET assay [PMID: 24856059]
HEK293-A EC50 0.2 μM Transactivation of PPARalpha expressed in HEK293A cells co-expressing GAL4 after 16 to 18 hrs by luciferase reporter gene assay [PMID: 23137448]
HEK-293T EC50 15.4 nM Agonist activity at GAL4-tagged PPARalpha ligand-binding domain (unknown origin) expressed in HEK293T cells incubated for 16 to 19 hrs by beta-lactamase reporter gene assay [PMID: 25491112]

19 records · Scroll to view more

In Vitro Studies

GW 7647 at 10 μM significantly increased PPARα mRNA levels in Huh-7 cells. In WT mouse hepatocytes treated for 24 h, the lowest benchmark concentrations for PPARα target genes were approximately 0.013 µM. In primary hepatocytes, treatment at 10 µM for 24 h decreased Lgr5 expression; downregulation observed with different doses in WT mouse hepatocytes was abolished in PPARα KO mouse cells. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

PPARα mRNA Expression in Huh-7 Cells

Cell-based study · Huh-7 cells [1]

Huh-7 cells were treated at 10 μM, with BSA as the control. Treatment significantly increased PPARα mRNA levels, assessed by real-time RT-PCR.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Real-time RT-PCR analysis of PPARαReported result GW7647 significantly increased PPARα mRNA levels[1]

Literature-Reported Treatment Conditions

Treatment concentration
10 μM
Exposure duration
24-hour-treated
Reported limits
Not stated in the sentences used: route, vehicle.
Methods and source locations

Compound reported in the paper: GW 7647

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > PPARα activation reverses palmitic acid-induced lipotoxicity (S151); Fig. 4 legend (S223)

Real-time RT-PCR analysis of PPARα: Real-time RT-PCR analysis of PPARα; comparator: BSA — Results > PPARα activation reverses palmitic acid-induced lipotoxicity (S151); Fig. 4 legend (S223)

Benchmark concentrations in WT mouse hepatocytes

Cell-based study · WT mouse hepatocytes [2]

WT mouse hepatocytes were treated with GW 7647 for 24 h. The lowest benchmark concentrations for PPARα target genes were approximately 0.013 µM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
lowest BMCs for PPARα target genesBMC WT hepatocytes, 24 h: approximately 0.013 µM[2]

Literature-Reported Treatment Conditions

Treatment concentration
0.01, 0.1, 1, or 10 μM
Exposure duration
24 h
Method
supplemented modified Eagle’s medium
Vehicle
dimethylsulfoxide (0.1%; cell culture grade; Sigma Aldrich)
Methods and source locations

Compound reported in the paper: GW 7647

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Materials and methods > Untitled > Untitled > Hepatocyte treatments (S16, S17, S18); Materials and methods > Untitled > Untitled > Differential gene expression analyses (S35); Results > Untitled > Benchmark concentration modeling of gene expression data from WT and PPARα KO mouse hepatocytes (S133)

lowest BMCs for PPARα target genes: lowest BMCs for PPARα target genes; comparator: solvent control — Results > Untitled > Benchmark concentration modeling of gene expression data from WT and PPARα KO mouse hepatocytes (S133)

Lgr5 expression in primary hepatocytes

Cell-based study · primary hepatocytes; n = 3 per group [3]

QRT-PCR analysis of Lgr5 expression in primary hepatocytes treated with GW7647 (10 µM) or DMSO for 24 h: decreasing Lgr5 expression. Additionally, different doses of GW7647 induces down-regulation of Lgr5 expression in hepatocytes from WT mice and was abolished in PPARα KO mouse cells.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
QRT-PCR analysis of PPARα, Cpt1a and Lgr5 expressionReported result GW7647 (10 µM) for 24 h: decreasing Lgr5 expression. Additionally, different doses of GW7647 induces down-regulation of Lgr5 expression in hepatocytes from WT mice and was abolished in PPARα KO mouse cells.[3]

Literature-Reported Treatment Conditions

Treatment concentration
10 µM
Exposure duration
24 h
Vehicle
DMSO
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: GW 7647

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Results > PPARα activation suppresses Lgr5 expression (S79, S80); Figure 2 legend (S141)

QRT-PCR analysis of PPARα, Cpt1a and Lgr5 expression: QRT-PCR analysis of PPARα, Cpt1a and Lgr5 expression; comparator: DMSO — Results > PPARα activation suppresses Lgr5 expression (S79, S80); Figure 2 legend (S141)

In Vivo Studies

Mice received GW 7647 orally at 5 mg/kg, with hepatic gene expression assessed by QRT-PCR. Treatment notably suppressed hepatic Lgr5 expression in WT mice, but this suppression was abolished in PPARα-/- mice. [3]

Hepatic Lgr5 expression in mice

Animal study · Mice; n = 5 per group [3]

Mice were orally treated with vehicle or GW7647 (5 mg/kg) 2 days of twice-daily routines in a row. QRT-PCR results revealed that PPARα agonist notably suppressed the expression of Lgr5 in WT, but this suppression effect was abolished in PPARα-/- mice.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
hepatic expression levels of Lgr5, Cpt1a and Acox1 were determined by QRT-PCR analysisReported result GW7647 (5 mg/kg): notably suppressed the expression of Lgr5 in WT, but this suppression effect was abolished in PPARα-/- mice.[3]

Conditions shared by the study groups

Route
orally
Treatment course
2 days of twice-daily routines in a row
Vehicle
80% PEG-400 and 20% Tween 80
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
GW 7647 5 mg/kgvehicleGW7647 (5 mg/kg): notably suppressed the expression of Lgr5 in WT, but this suppression effect was abolished in PPARα-/- mice.[3]
GW 7647 5 mg/kg
Model: Mice; n = 5 per group
Methods and source locations

Compound reported in the paper: GW 7647

Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.

Methods (S4); Results > PPARα activation suppresses Lgr5 expression (S87, S88); Figure 2 legend (S142, S143)

hepatic expression levels of Lgr5, Cpt1a and Acox1 were determined by QRT-PCR analysis: hepatic expression levels of Lgr5, Cpt1a and Acox1 were determined by QRT-PCR analysis; comparator: vehicle — Results > PPARα activation suppresses Lgr5 expression (S87, S88); Figure 2 legend (S142, S143)

GW 7647 5 mg/kg · Results > PPARα activation suppresses Lgr5 expression (S87, S88); Figure 2 legend (S142)

Specifications

Manufacturer Adooq Bioscience
Actions Agonist
CAS Number 265129-71-3
Applications PPARα agonist
Formula C29H46N2O3S
Molecular Weight 502.75
SMILES
CC(C)(C(=O)O)SC1=CC=C(C=C1)CCN(CCCCC2CCCCC2)C(=O)NC3CCCCC3

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Moliterni C, Vari F, Schifano E, et al. Lipotoxicity of palmitic acid is associated with DGAT1 downregulation and abolished by PPARα activation in liver cells. J Lipid Res (2024). PMID: 39505261 DOI: 10.1016/j.jlr.2024.100692 Source material
  2. [2] Heintz MM, Klaren WD, East AW, et al. Comparison of transcriptomic profiles between HFPO-DA and prototypical PPARα, PPARγ, and cytotoxic agents in wild-type and PPARα knockout mouse hepatocytes. Toxicol Sci (2024). PMID: 38574385 DOI: 10.1093/toxsci/kfae045 Source material
  3. [3] Qin D, Liu S, Lu Y, et al. Lgr5 + cell fate regulation by coordination of metabolic nuclear receptors during liver repair. Theranostics (2022). PMID: 36168631 DOI: 10.7150/thno.74194 Source material

Added to your cart

View Cart Checkout
Loading...